The accuracy of using administrative healthcare data to identify epilepsy cases: A systematic review of validation studies by Mbizvo, Gashirai K. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The accuracy of using administrative healthcare data to identify
epilepsy cases: A systematic review of validation studies
Citation for published version:
Mbizvo, GK, Bennett, KH, Schnier, C, Simpson, CR, Duncan, SE & Chin, RFM 2020, 'The accuracy of using
administrative healthcare data to identify epilepsy cases: A systematic review of validation studies',
Epilepsia. https://doi.org/10.1111/epi.16547
Digital Object Identifier (DOI):
10.1111/epi.16547
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Epilepsia
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 21. Jun. 2020
Epilepsia. 2020;00:1–17.    | 1wileyonlinelibrary.com/journal/epi
Received: 30 July 2019 | Revised: 28 April 2020 | Accepted: 29 April 2020
DOI: 10.1111/epi.16547  
C R I T I C A L  R E V I E W  A N D  I N V I T E D  C O M M E N T A R Y
The accuracy of using administrative healthcare data to identify 
epilepsy cases: A systematic review of validation studies
Gashirai K. Mbizvo1  |   Kyle H. Bennett1  |   Christian Schnier2 |   Colin R. Simpson2,3  |  
Susan E. Duncan1,4  |   Richard F.M. Chin1,5
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy
1Muir Maxwell Epilepsy Centre, Centre for 
Clinical Brain Sciences, The University of 
Edinburgh, Edinburgh, UK
2Usher Institute of Population Health 
Sciences and Informatics, The University of 
Edinburgh, Edinburgh, UK
3School of Health, Faculty of Health, 
Victoria University of Wellington, 
Wellington, NZ
4Department of Clinical Neurosciences, 
Western General Hospital, Edinburgh, UK
5Royal Hospital for Sick Children, 
Edinburgh, UK
Correspondence
Gashirai K. Mbizvo, Muir Maxwell 
Epilepsy Centre, Child Life and Health, 20 
Sylvan Place, EH9 1UW, Edinburgh, UK.
Email: gashiraimbizvo@hotmail.com
Funding information
Epilepsy Research UK, Grant/Award 
Number: R44007; The Juliet Bergqvist 
Memorial Fund, Grant/Award Number: N/A
Abstract
Our objective was to undertake a systematic review ascertaining the accuracy of using 
administrative healthcare data to identify epilepsy cases. We searched MEDLINE 
and Embase from 01/01/1975 to 03/07/2018 for studies evaluating the diagnostic 
accuracy of routinely collected healthcare data in identifying epilepsy cases. Any 
disease coding system in use since the International Classification of Diseases, Ninth 
Revision (ICD-9) was permissible. Two authors independently screened studies, 
extracted data, and quality-assessed studies. We assessed positive predictive value 
(PPV), sensitivity, negative predictive value (NPV), and specificity. The primary 
analysis was a narrative synthesis of review findings. Thirty studies were included, 
published between 1989 and 2018. Risks of bias were low, high, and unclear in 
4, 14, and 12 studies, respectively. Coding systems included ICD-9, ICD-10, and 
Read Codes, with or without antiepileptic drugs (AEDs). PPVs included ranges of 
5.2%–100% (Canada), 32.7%–96.0% (USA), 47.0%–100% (UK), and 37.0%–88.0% 
(Norway). Sensitivities included ranges of 22.2%–99.7% (Canada), 12.2%–97.3% 
(USA), and 79.0%–94.0% (UK). Nineteen studies contained at least one algorithm 
with a PPV >80%. Sixteen studies contained at least one algorithm with a sensitivity 
>80%. PPV was highest in algorithms consisting of disease codes (ICD-10 G40-41, 
ICD-9 345) in combination with one or more AEDs. The addition of symptom codes 
to this (ICD-10 R56; ICD-9 780.3, 780.39) lowered PPV. Sensitivity was highest in 
algorithms consisting of symptom codes with one or more AEDs. Although using 
AEDs alone achieved high sensitivities, the associated PPVs were low. Most NPVs 
and specificities were >90%. We conclude that it is reasonable to use administrative 
data to identify people with epilepsy (PWE) in epidemiological research. Studies 
prioritizing high PPVs should focus on combining disease codes with AEDs. Studies 
prioritizing high sensitivities should focus on combining symptom codes with AEDs. 
We caution against the use of AEDs alone to identify PWE.
[Correction added on June 09, 2020, after first online publication: "USA" was removed from affiliation 3.] 
2 |   MBIZVO et al.
1 |  INTRODUCTION
Administrative healthcare data consist of routine diagnos-
tic and procedural information collected about patients 
when they use healthcare services.1 These national data 
sets are widely available and less-intrusive potential re-
sources for medical research.1 However, their diagnostic 
accuracy requires validation because the data were col-
lected originally for routine nonscientific purposes. Poor 
or incomplete hospital discharge letters and clinical coding 
errors are examples of potential sources for administrative 
data inaccuracies.2 Systematic reviews of administrative 
data validation studies increase confidence in case-ascer-
tainment accuracy estimates for a particular condition and 
scrutinize the quality of available evidence.3-11 To date, 
there has been only one systematic review of studies vali-
dating the accuracy of administrative epilepsy data sets.12 
Although this was helpful, the 11 studies reviewed were 
from the United States and Canada alone and published up 
to the year 2010 only. The International Classification of 
Diseases, Ninth Revision (ICD-9) system was used in all 
but one study, and the review lacked a risk of bias assess-
ment. We now provide an updated systematic review of 
epilepsy validation studies worldwide. We include risk of 
bias assessments and evaluate ICD-9, ICD-10, and other 
coding systems routinely used.13,14 We focus on positive 
predictive value (PPV) and sensitivity, as these are the 
most commonly reported validation outcomes in the litera-
ture.11,12 However, we also report negative predictive value 
(NPV) and specificity, where available.
2 |  METHODS
The aims and inclusion criteria were established before 
conduct of the review and the a priori study protocol was 
registered on PROSPERO (CRD42017081212-https://bit.
ly/2VOdoNj),15 and published.16 The review follows the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) system of reporting.17 Ethical approval 
was not required.
2.1 | Eligibility criteria
We included studies according to the following criteria:
• Study country: No restrictions;
• Language: No restrictions: translations were sought for 
any non-English texts;
• Study design: No study type was excluded;
• Participants: People with epilepsy of all ages;
• Validated database: Studies evaluating the diagnostic ac-
curacy of routinely collected (administrative) healthcare 
data using ICD-9, ICD-10, or any other diagnostic coding 
system in use since the advent of ICD-9 in 197518;
• Reference standard: There were no minimum requirements 
for the types of gold standard used. The risk of study bias 
was assessed using the Quality Assessment of Diagnostic 
Accuracy Studies 2 (QUADAS-2) tool19;
• Observations and outcomes: Studies had to report at least 
a PPV, sensitivity, NPV, or specificity estimate, or provide 
data from which these could be calculated;
• Timeframe: Studies conducted from 01/01/1975 onward.
2.2 | Information sources, literature 
searches, and study selection
MEDLINE and Embase (including Embase gray litera-
ture)15,20,21 were searched from 01/01/1975 to 03/07/2018 
(date last searched: 04/07/2018) for potentially eligible stud-
ies (see Appendix  S1 for search strategy). Reference lists 
of manuscripts screened were also searched to identify po-
tentially eligible studies. Any studies made aware to us by 
colleagues were also screened. Two authors (GKM and KB) 
independently screened titles, abstracts, or full-length articles 
for eligibility and inclusion, with disagreements resolved by 
K E Y W O R D S
diagnostic test accuracy, international classification of diseases, positive predictive value, routine data, 
seizures, sensitivity
Key Points
• Administrative healthcare data can be used confi-
dently to identify people with epilepsy in epide-
miological research.
• Studies prioritizing high positive predictive values 
should focus on combining disease codes with an-
tiepileptic drugs.
• Studies prioritizing high sensitivities should focus 
on combining symptom codes with antiepileptic 
drugs.
• Antiepileptic drugs alone are unlikely to accu-
rately capture persons with epilepsy from admin-
istrative data.
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consensus or, where necessary, third reviewer adjunction 
(RFMC).
2.3 | Data abstraction
GKM and KB independently abstracted data pertaining to 
study location, participant age, administrative data setting, 
coding system, sample size, algorithm(s), reference standard 
details, PPV, sensitivity, NPV, specificity, and confidence 
intervals (CIs). We used a pre-piloted data abstraction form 
(Appendix  S2). We made attempts to collect any relevant 
missing or unpublished study data by contacting the corre-
sponding study author by email. We settled any differences in 
abstracted data by mutual review of the relevant study article.
2.4 | Quality assessment
We assessed the risk of bias and applicability concern 
for included studies using the Quality Assessment of 
Diagnostic Accuracy Studies 2 (QUADAS-2)19 tool adapted 
by Wilkinson et al11 for administrative validation studies 
(Table 1). GKM and KB independently graded each study's 
risk of bias and applicability concern as low, unclear, or high 
across the four categories: patient selection, administrative 
database (“index test”), reference standard, and study par-
ticipant flow.19 We used the QUADAS-2 abstraction form 
in Appendix S3 (16 quality decisions per study), with disa-
greements resolved by consensus or, where necessary, third 
reviewer adjunction (RFMC).
2.5 | Summary measures and 
synthesis of results
Cohen's kappa statistic was used estimate interrater agree-
ment (above chance) between GKM and KB for study eligi-
bility selection and QUADAS-2 quality assessment.22,23 We 
reported all of the algorithms and associated PPVs, sensitivi-
ties, NPVs, and specificities for epilepsy provided by each 
study, but we excluded any algorithms attempting to further 
identify epilepsy by seizure type or epilepsy syndrome to re-
duce clinical heterogeneity of the condition being assessed. 
The primary analysis was a narrative synthesis of results for 
PPV, sensitivity, NPV, and specificity.10-12,24 This included 
results summarized as ranges across studies for different 
countries to assist in correcting for potential differences in 
epilepsy prevalence between different countries and also to 
facilitate reporting and interpreting results from a wide range 
of countries (each with potentially varying coding practices). 
Results were also summarized as ranges across studies exclu-
sively using medical records as their diagnostic gold standard 
to allow interpretation of results when applied across a con-
sistent optimal reference standard. We created forest plots 
consisting of the best and worst PPV, sensitivity, NPV, and 
specificity from each study, allowing us to discuss the study 
characteristics and diagnostic algorithms associated with the 
best cases and worst cases of PPV, sensitivity, NPV, and 
specificity. We did not pool PPV and NPV estimates into a 
formal meta-analysis, as this approach is cautioned against 
owing to the expected heterogeneity from variation in disease 
prevalence and different disease positivity thresholds.11,12,24 
We used a Reitsma random-effects bivariate meta-analysis 
model to estimate a summary sensitivity and specificity be-
cause these two outcomes are relatively resilient to changes in 
disease prevalence.25,26 This analysis is only possible across 
studies providing all of the true positives, false positives, true 
negatives, and false negatives.26 All estimates were reported 
with 95% CIs where possible. We considered participants 
aged ≥18 years as adults and <18 years children. Data were 
processed and analyzed using rstudio Version 1.2.1335, 
Boston, MA: RStudio, Inc.
3 |  RESULTS
3.1 | Search and study characteristics
Thirty studies14,27-55 were included from 197 potentially eli-
gible records (Figure  1). The level of study selection agree-
ment between authors was graded as moderate,23 detailed 
in Appendix  S4. Twenty-seven studies were identified from 
searching MEDLINE and Embase, and three36,50,55 were identi-
fied from hand-searching the reference lists of potentially eligi-
ble studies. One study had unpublished validation outcome data 
for epilepsy, which were kindly provided to us separately by the 
corresponding author upon request.40 The included studies were 
all published between 1989 and 2018 (only two before 2000).31,49 
All were carried out in high-income countries. Excluded studies 
are listed in Appendix S5.21 Participants were adults in eight 
studies,29,33,40,42,46,48,52,53 children in two studies,27,41 both adults 
and children in 14 studies,14,28,34-39,43,49-51,54,55 and unclear age 
in six studies.30-32,44,45,47 Epilepsy was the target diagnostic 
condition in all included studies. The majority (19 studies) used 
hand-searched medical records as the diagnostic gold stand-
ard.14,30,32,37-43,45-48,50-54 In the remaining 11 studies, the other 
gold standards used were the general practitioner (GP: 3 stud-
ies),35,36,49 being on antiepileptic drugs (AEDs: three studies, 
one of which used rufinamide only),31,33,44 medical records and/
or parent telephone interview,27 an epilepsy center patient list,28 
a previous epilepsy prevalence study,29 another administrative 
data set,34 and a specialist epilepsy database.55 Administrative 
data sets validated included inpatients, outpatients, pharmacy, 
accident and emergency, physician claims, and primary care. 
Algorithms included ICD-9, ICD-10 (including two studies 
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that combined ICD-8 and ICD-10 data sets together),30,52 Read 
Codes (Version 2), AEDs, hospitalizations, and procedures 
such as electroencephalography (EEG) or vagus nerve stimula-
tion (VNS). Twenty-eight studies assessed PPV,14,27-43,45-54 of 
which 14 also assessed sensitivity.14,28,29,33-35,37,38,40,42,48,51,52,54 
Two studies assessed sensitivity alone.44,55 Fourteen studies as-
sessed NPV and specificity,14,28,29,33-35,37,38,40,42,48,51,52,54 and 
one study assessed specificity without NPV.44
3.2 | Quality assessment
The mean level of quality assessment agreement between au-
thors was graded as fair,23 detailed in Appendix  S6A. Four 
studies had low risks of bias and low applicability concerns 
across all categories (Appendix  S6B). Fourteen studies had 
one or more high-risk ratings. High risks of bias from reference 
standard conduct were common. This was largely due to inad-
equate blinding of the reference standard reader,35,36,49 use of 
unvalidated administrative data sets as the reference standard,34 
and use of AEDs as the reference standard.31,33,44 High risks of 
bias from study flow and timing were also common, largely due 
to all study participants not receiving the same reference stand-
ard,27,34,36,40 or due to the diagnostic alternatives of “epilepsy” 
or “not epilepsy” for missing participants not being explored 
in a “best-case” or “worst-case” sensitivity analysis, respec-
tively.14,49,54 The remaining 12 studies had ratings of both low 
and unclear risks across different categories, resulting in over-
all risks being graded unclear.28,32,37,41-43,45-47,50,52,55 The most 
common reason for this was lack of clarity about whether or not 
those reading the reference standard were blinded to the partici-
pants’ administrative codes.
3.3 | Narrative analysis
3.3.1 | Overall PPV and sensitivity
Overall, 28 studies generated 172 algorithms estimating 
PPV and 121 of these algorithms (generated by 13 studies) 
F I G U R E  1  Flow diagram of study 
selection process. The three studies 
identified from hand-searching reference 
lists of screened literature were Pickrell 
201555 (found in the included study 
Fonferko-Shadrach 201714), Syvertsen 
201550 (found in the excluded study Aaberg 
201659), and Frost 200036 (found in the 
systematic review Kee 201212)
6 |   MBIZVO et al.
also estimated sensitivity. Figure 2A,B illustrates the range 
of these PPV and sensitivity results (arranged by country). 
There was no clear visual pattern11 to suggest that any par-
ticular country's PPVs or sensitivities performed better than 
another's. Figure 2C,D illustrates the range of PPVs and sen-
sitivities arranged by overall risks of bias or applicability 
concern. A larger proportion of PPVs (81% of 70 algorithms) 
and sensitivities (83% of 46 algorithms) from low-risk stud-
ies were of a high magnitude (>80%). By contrast, a smaller 
proportion of PPVs (12% of 57 algorithms) and sensitivi-
ties (52% of 42 algorithms) from high-risk studies were of 
a high magnitude (>80%). For unclear-risk studies, a small 
proportion of PPVs (33% of 45 algorithms) and sensitivities 
(29% of 35 algorithms) were of a high magnitude (>80%). 
Figure 3A,B illustrates the range of these PPV and sensitivity 
results grouped by the 19 studies exclusively using medical 
records as the diagnostic gold standard against the 11 stud-
ies that used the other methods. PPV ranged 5.2%–100% 
and sensitivity ranged 61.0%–100% across the studies using 
medical records as the diagnostic gold standard. PPV ranged 
5.0%–93.0% and sensitivity ranged 36.6%–97.3% across the 
studies using other methods as the diagnostic gold standard. 
The lookup table in Appendix S7 ranks all the algorithm re-
sults from highest to lowest PPV alongside their sensitivity 
results (where available), other associated study characteris-
tics, and overall risks of study bias or applicability concern.
Figure  4A,B demonstrates the optimal diagnostic PPV 
and sensitivity algorithms, respectively, taken from each 
study and arranged in a forest plot. At their best, PPV or 
sensitivity were >80% in the majority of studies (19 of 
28 studies for PPV and 12 of 16 studies for sensitivity). 
From visual inspection11 of these figures, it was difficult 
to appreciate any potential effect of varying diagnostic gold 
standards used on optimal PPV and sensitivity estimates be-
cause hand-searched medical records predominated the gold 
standards used across studies. Inspecting the figures11 oth-
erwise revealed that the high PPV and sensitivity estimates 
>80% appeared to cross multiple different coding systems 
and algorithms used (including ICD-8, ICD-9, ICD-10, or 
Read Codes with and without AEDs or procedures), across 
various population ages and settings including accident and 
emergency, inpatients, outpatients, and primary care. Nearly 
all of the studies with an optimal PPV ≤80% had a high risk 
of bias or applicability concern (six of nine studies, with 
unclear risks in the remaining three studies, Figure 4A). The 
quality ratings were more variable for studies generating op-
timal sensitivity algorithms (Figure 4B). Studies providing 
multiple within-study PPVs and sensitivities were used to 
generate forest plots illustrating the worst-performing di-
agnostic PPV and sensitivity algorithms, respectively, in 
Figure  5A,B. These figures illustrate that PPV was low, 
<80%, in 19 of the 20 worst-performing PPV algorithms, 
and sensitivity was <80% for nine of the 10 worst-per-
forming sensitivity algorithms. Once again, hand-searched 
medical records predominated the diagnostic gold standard 
across this comparison.
F I G U R E  2  Positive predictive value (PPV, %) and sensitivity (%) dot plots: Dots represent the PPV or sensitivity for each algorithm 
provided by studies, organized by country (2A = PPV, 2B = sensitivity), and by Quality Assessment of Diagnostic Accuracy Studies 2 
(QUADAS-2)19 score for overall risk of study bias or applicability concern (2C = PPV, 2D = sensitivity)
   | 7MBIZVO et al.
3.4 | PPVs and sensitivities by country
3.4.1 | Canada
Positive predictive value ranged from 5.2%–100% and 
sensitivity ranged from 22.2%–99.7% across six Canadian 
studies (Appendix S7).34,38,40,48,52,54 Jetté 201038 and Reid 
201248 had low risks of bias and applicability concerns 
(Appendix  S6B). All but one study (Foebel 201334) used 
medical records as their diagnostic gold standard, and PPV 
and sensitivity range remained 5.2%–100% and 22.2%–
99.7%, respectively, across these five studies. Jetté 201038 
estimated an optimal PPV for epilepsy of 100% (95% CI 
93.2%–100%) for ICD-10 codes G40 (epilepsy) and G41 
(status epilepticus) combined (Figure  4A). The addition 
of ICD-10 code R56 (convulsions) lowered this PPV to a 
worst estimate of 71.6% (CI 60.5%–80.6%, Figure 5A). The 
sensitivity for G40-41 was 98.8% (CI 93.3%–99.8%) and 
was not tested with R56. The study also tested the PPVs of 
ICD-9 coding and found that performance between ICD-9 
and ICD-10 was similar, and that there was also little dif-
ference between results for children and adults. Reid 201248 
tested algorithms consisting of ICD-9 code 345 (epilepsy) 
or ICD-10 G40-41 when used as various combinations of 
physician claims, hospitalizations, or accident and emer-
gency visits over 1-2  years. Spreading these codes over 
one physician claim, one hospitalization, or one accident 
and emergency visit over 2 years had the highest sensitiv-
ity (99.7%, CI 99.3%–100%, Figure 4B), demonstrating an 
ability to capture almost all persons with epilepsy in the 
population, albeit with the trade-off of also giving the worst 
PPV of 81.6% (CI 79.0%–84.2%, Figure 5A),56 indicating 
that many false positives were also captured by this use of 
multiple sites. By limiting to those algorithms with two 
physician claims over 1 year, PPV was raised to an optimal 
of 92.1% (CI 90.1%–94.1%, Figure  4A) at a trade-off of 
lowering sensitivity to, at worst, 86.2% (CI 83.3%–90.2%, 
Figure 5B); suggesting that a good proportion of the epi-
lepsy population was still captured. Williamson 201454 val-
idated primary care using ICD-9 codes and had high risks 
of bias or applicability concerns (Appendix S6B). The algo-
rithm was epilepsy ICD-9 345 or convulsions 780.3 (with 
a requirement for AEDs in “petit mal” 345.2, “grand mal” 
345.3, or in 780.3). This generated a very high sensitivity of 
98.6% (CI 96.6%–100%, Figure 4B) with a trade-off of PPV 
85.6% (CI 80.2%–91.1%, Figure  4A), perhaps suggesting 
F I G U R E  3  Gold standard method 
dot plots: Dots represent the PPV (3A, %) 
or sensitivity (3B, %) for each algorithm, 
grouped by whether the reference 
standard used was exclusively medical 
records or other methods (ie, the general 
practitioner,35,36,49 antiepileptic drugs,31,33,44 
medical records and/or parent telephone 
interview,27 an epilepsy center patient list,28 
a previous epilepsy prevalence study,29 
another administrative data set,34 or a 
specialist epilepsy database)55
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that the convulsions code in ICD-9 lowers PPV similarly 
to the ICD-10 convulsions code R56, as was seen in Jetté 
2010.38 Other studies included the Tu 201452 study, which 
had an unclear risk of bias and tested an algorithm consist-
ing of ICD-8 345 (epilepsy), ICD-9 345, or ICD-10 G40 
as hospitalization or physician claims over varying times. 
The optimal PPV of 81.7% (CI 73.3%–90.1%, Figure 4A) 
was generated by one hospitalization or four physician 
claims separated by ≥30 days within a 3-year period and 
greatly contrasted with the worst PPV of 36.8% (CI 30.6%–
42.9%, Figure 5A) generated by only one hospitalization or 
physician claim. However, this poor PPV was associated 
with a trade-up in sensitivity to 90.5% (CI 84.6%–96.4%, 
Figure 4B). The worst sensitivity consisted of hospitaliza-
tion alone (33.7%, CI 24.2%–43.2%) indicating that hos-
pitalization alone is not a reliable way of capturing all 
persons with epilepsy. Another study, by Marrie 2013,40 
validated epilepsy codes as a comorbidity of multiple scle-
rosis and had high risks of bias and low PPV and sensitivity 
estimates (with wide CIs, Figures 4 and 5, Appendix S7). 
These results were difficult to interpret in the context of the 
different algorithms provided. Foebel 201334 had high risks 
of bias and validated ICD-10 G40 or Resident Assessment 
Instrument (RAI) 2.0 pick list items within psychiatric in-
patients, long-term care, and complex continuing care, gen-
erating low PPV and sensitivity estimates, which suggests 
that these environments and/or pick list items brought inac-
curacy to estimates (Figures 4 and 5). It is possible that the 
study's use of an administrative data set as the diagnostic 
gold standard compounded the poorer accuracy estimates.
3.4.2 | United States
Positive predictive value and sensitivity ranged from 32.7%–
96.0% and 12.2%–97.3%, respectively, across nine US studies 
(Appendix S7).32,36,37,42-47 Risks of bias and applicability con-
cern were unclear in all but two studies,36,44 where risks were 
F I G U R E  4  Forest plot showing the optimal diagnostic algorithms (4A = highest positive predictive value [PPV, %], 4B = highest 
sensitivity [%]) in each included study that estimated PPV or sensitivity, alongside various study characteristics. * = Studies that provided 
one PPV or sensitivity algorithm only. Bias = Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2)19 score for overall risk of 
study bias or applicability concern for that study. A and E: Accident and emergency; AED: Antiepileptic drug; CI: Confidence interval (%); 
EEG: Electroencephalography; EXE: Exception code; F25, 1O30, 667B., SC200: Epilepsy Read Codes; H: Hospitalization; ICD: International 
Classification of Diseases; ICD10 F80.3: Acquired aphasia with epilepsy; ICD10 G40: Epilepsy; ICD10 G41; Status epilepticus; ICD8 345: 
Epilepsy; ICD9 311, 300.4, 300, 300.02: Anxiety and depression codes; ICD9 333.2: Myoclonus; ICD9 345: Epilepsy; ICD9 779: Perinatal illness; 
ICD9 780.2: Syncope and collapse; ICD9 780.3: Convulsions; ICD9 780.31: Febrile convulsions; ICD9 780.39: convulsions; P: Physician claim; 
RAI: Resident Assessment Instrument; VNS: Vagus nerve stimulation; Yr: year
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high (Appendix S6B). Six US studies used medical records 
as their diagnostic gold standard (PPV range 48.0%–96.0%, 
sensitivity range 12.2%–81.8%).37,42,43,45-47 The US studies all 
tested ICD-9 codes, including at least ICD-9 345 (epilepsy) 
and either 780.3 or 780.39 (seizures). When these diagnostic 
codes were looked at without a requirement for AEDs, PPV 
ranged between 48.0% and 90.0% (seven algorithms from five 
studies),32,37,42,43,45 with PPV <80% in four of the seven algo-
rithms. When diagnostic codes were looked at with a require-
ment for AEDs, PPV ranged between 58.4% and 94.0% (nine 
algorithms from four studies).37,42,46,47 PPV was <80% in only 
two of nine algorithms, indicating that an AED requirement 
increased the likelihood of higher PPV estimates. When diag-
nostic codes were looked at with a requirement for AEDs and 
procedures (EEG or VNS), PPV ranged between 32.7% and 
86.9% (four algorithms from three studies,36,37,42 with two al-
gorithm PPVs <80%). The best and worst algorithm combina-
tions from the United States are shown in Figures 4 and 5. In 
the Parko 200943 study, the algorithm ICD-9 345 or 780.3 had 
a PPV of 90.0% (CI 88.4%–91.7%) when capturing epilepsy 
or seizures (Figure 4A), and fell to 62.0% (CI 59.3-64.7) when 
capturing epilepsy. ICD-9 345 without 780.3 was not tested.
3.4.3 | United Kingdom
Positive predictive value and sensitivity ranged from 
47.0%–100% and 79.0%–94.0%, respectively, across four 
UK studies (Appendix S7).14,31,41,55 Two studies (Fonferko-
Shadrach 201714 and Meeraus 201341) used medical records 
as their diagnostic gold standard (PPV range 71.0%–100%, 
sensitivity range 79.0%–94.0%). The Fonferko-Shadrach 
201714 study had a high risk of bias or applicability con-
cern (Appendix S6B). This study demonstrated that within 
Read Codes, two prescriptions of the same AED within 
6 months provided the optimal sensitivity (94.0%, CI 
87.0%–98%, Figure 4B), capturing nearly all persons with 
epilepsy. However, many false positives were also cap-
tured, generating the lowest PPV (71.0%, CI 63.0%–78.0%, 
Figure 5A). This was in participants >16 years of age and 
rose to 98% (CI 94%–100%) in participants ≤16 years of 
age. AEDs are seldom prescribed for indications other than 
epilepsy in children in the UK.14 This was the only included 
study to allow direct comparison of AEDs alone between 
adults and children. Diagnostic epilepsy Read Codes com-
bined with two AED prescriptions in 6 months generated 
F I G U R E  5  Forest plot showing the worst-performing diagnostic algorithms (5A = lowest positive predictive value [PPV, %], 5B = lowest 
sensitivity [%]) in each included study that estimated PPV or sensitivity, alongside various study characteristics. Bias = Quality Assessment of 
Diagnostic Accuracy Studies 2 (QUADAS-2)19 score for overall risk of study bias or applicability concern for that study. A and E: Accident and 
emergency; AED: Antiepileptic drug; CI: Confidence interval (%); EEG: Electroencephalography; EXE: Exception code; F25, 1O30, 667B., 
SC200: Epilepsy Read Codes; H: Hospitalization; ICD: International Classification of Diseases; ICD10 F80.3: Acquired aphasia with epilepsy; 
ICD10 G40: Epilepsy; ICD10 G41; Status epilepticus; ICD8 345: Epilepsy; ICD9 311, 300.4, 300, 300.02: Anxiety and depression codes; ICD9 
333.2: Myoclonus; ICD9 345: Epilepsy; ICD9 779: Perinatal illness; ICD9 780.2: Syncope and collapse; ICD9 780.3: Convulsions; ICD9 780.31: 
Febrile convulsions; ICD9 780.39: Convulsions; P: Physician claim; RAI: Resident Assessment Instrument; VNS: vagus nerve stimulation; Yr: 
year
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the highest PPV (100%, CI 91.0%–100%, Figure 4A), at a 
trade-off of slightly poorer sensitivity (79.0%, CI 65.0%–
90.0%, Figure  5B). PPVs and sensitivities for diagnostic 
Read Codes alone ranged between 93.0% and 98.0% and 
83.0% and 88.0%, respectively. Pickrell 201555 had unclear 
risks of bias (Appendix S6B) and demonstrated a similar 
sensitivity result (90.5%, CI 89.2%–91.8%) to Fonferko-
Shadrach 201714 by also using diagnostic epilepsy Read 
Codes combined with two AED prescriptions, although 
over 12 months. Pickrell 201555 used a specialist epilepsy 
database as the diagnostic gold standard. Meeraus 201341 
had unclear risks of bias and demonstrated high PPVs for 
Read Code epilepsy diagnosis, symptoms, or AED prescrip-
tion repeated within 4 months (92.0%, CI 88.0%–96.0%). 
Coulter 1989,31 the oldest included study, had high risks 
of bias. The chronic primary care disease register validated 
was found to have a poor PPV (47.0%, CI 42.0%–52.0%). 
It is possible that this was compounded by the study's use 
of AEDs as a diagnostic gold standard.
3.4.4 | Norway
Positive predictive value ranged from 37.0%–88.0% across 
three Norwegian studies (Appendix  S7).27,33,50 Risks of 
bias were high in all but one study, which had unclear risks 
(Appendix S6B).50 This same study (Syvertsen 201550) was 
the only one to exclusively use medical records as the di-
agnostic gold standard (PPV 80%). Both Syvertsen 201550 
and Aaberg 201727 validated ICD-10 code G40 alone (two 
or more registrations in Aaberg 2017)27 and achieved good 
optimal PPVs ranging from 80%–88% (Figure 4A). Reducing 
to one or more registrations lowered PPV to 66.0% (CI 
63.0%–69.0%, Figure  5A).27 Aaberg 201727 used medical 
records and/or parent telephone interview as the diagnostic 
gold standard. Engeland 200933 validated a maternal disease 
registry to capture epilepsy in pregnant women using ICD-10 
(codes were not further specified), identifying globally poor 
estimates of PPV 37.0% (CI 34.0%–40.0%, Figure 4A) and 
sensitivity 74.0% (CI 69.0%–78.0%, Figure 4B). It is possible 
that this was compounded by the study's use of AEDs as the 
diagnostic gold standard.
3.4.5 | Italy
Positive predictive value ranged from 13.6%–81.1% and 
sensitivity ranged from 36.6%–90.1% across two Italian 
studies (Appendix S7), one using the GP35 and the other an 
epilepsy center patient list28 as the diagnostic gold stand-
ard. Risks of bias were high in Franchi 201335 and unclear 
in Bellini 201728 (Appendix  S6B). The highest PPV came 
from the former study's use of lone exemption codes (EXE) 
for epilepsy 017 (based on ICD-9): 81.1% (CI 64.3%–91.4%, 
Figure 4A).35 These are codes that qualify people with epi-
lepsy for free-of-charge healthcare. However, sensitivity was 
low (42.3%, CI 30.8%–54.5%) indicating that these were 
not able to capture all persons with epilepsy. The addition 
of AEDs to exemption codes or to diagnostic ICD-9 codes 
(or use of AEDs alone) dropped PPV to its worst (13.6%, CI 
10.7%–17.2%, Figure 5A). Correspondingly, sensitivity was 
highest from use of the diagnostic ICD-9 or exemption codes 
with an additional requirement for AEDs or from AEDs alone 
(90.1%, CI 81.0%–95.1%, Figure 4B).35 Bellini 201728 used 
a complex case-ascertainment algorithm arranged as follows: 
[≥1 ICD-9 345 code] and/or [≥1 EEG recorded in a person 
prescribed ≥2 AEDs over 12 months] and/or [≥2 prescrip-
tions of one epilepsy-specific AED over 12  months]. This 
algorithm had a good sensitivity (87.3%, CI 84.9%–89.7%, 
Figure  4B) at a trade-off of generating a particularly low 
PPV (21.2%, CI 19.6%–22.4%, Figure 4A), suggesting that 
despite capturing most epilepsy cases there were many addi-
tional false positives. The PPV and sensitivity ranges across 
nine algorithms that included codes for procedures (EEG) 
were 21.2%–64.2% and 85.9%–88.7%, respectively.28,35 PPV 
and sensitivity ranges across seven algorithms without pro-
cedures were 13.6%–81.1% and 36.6%–90.1%, respectively, 
suggesting that there was a more stable tendency for good 
sensitivity when procedures were included but PPVs were 
variable (Appendix S7).
3.4.6 | The Netherlands
Positive predictive value ranged from 5.0%–99.0% across 
two Dutch studies (Appendix  S7), one using the GP49 and 
the other medical records53 as the diagnostic gold stand-
ard. Risks of bias or applicability concern were high for 
both studies (Appendix S6B). AED monotherapy or ICD-9 
coding without AEDs tended to perform poorly, with PPV 
range 5.0%–77.0% for the former notwithstanding require-
ment for continuous prescription over more than 1 year, and 
PPV 50.0 (CI 30.0%–70.0%) for the latter notwithstanding 
requirement for two attendances over 3 years. Polytherapy 
(>1 AED) improved PPV to 93.0% (CI 88.0%–98.0%), and 
adding in ICD-9 codes to the AED algorithm improved PPV 
to 95.0%–99.0%.
3.4.7 | Other countries
Little additional information was gained from the findings 
of countries within which only one study was conducted. 
These studies are summarized in Appendix S8 (Denmark,30 
Australia,51 South Korea,39 Taiwan).29 In the South Korean 
study (gold standard medical records), one or more AEDs 
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alone generated a worst PPV of 6.6% (CI 6.6%–6.7%, 
Figure  5A), reinforcing the potential problems of using 
AEDs alone.39
3.5 | Overall NPV and specificity
Less than half of the studies provided data on NPV and 
specificity: 14 studies, generating 131 algorithms estimat-
ing NPV (range 13.2%–100%), with 121 of these algorithms 
also estimating specificity (range 61.0%–100%).14,28,29,33-
35,37,38,40,42,48,51,52,54 One study provided specificity (95.6%) 
without NPV.44 Figures 6 and 7 illustrate the range of these 
NPV and specificity results, arranged by country (Figure 
6A,B), study quality score (Figure 6C,D), and gold standard 
method (Figure 7A,B). Nearly all of the NPV estimates (93% 
of 131 algorithms) and specificity estimates (95% of 122 
algorithms) were high, >80%, with little visible influence 
seen from grouping by country or study quality (Figure 6). 
Grouping by gold standard method suggested that the highest 
NPV and specificity estimates were found in the studies using 
methods other than medical records as the gold standard: All 
20 algorithms from five studies generated NPVs >97% and all 
21 algorithms from six studies generated specificities >94% 
(Figure 7). Figure 8A,B demonstrates the optimal NPV and 
specificity algorithms taken from each study and arranged in 
a forest plot. In each figure, all but one algorithm generated 
a very high NPV or specificity (>90%). This holds true de-
spite multiple different coding systems and algorithms used, 
across various population ages and settings, and between dif-
ferent countries. Most studies used medical records as their 
diagnostic gold standard. The worst-performing NPV and 
specificity algorithms (Figure  9A,B) demonstrated similar 
trends, with nearly all achieving stable estimates >80%–90% 
despite varying study characteristics. NPV and specificity es-
timates are also included in the Appendix S7 look-up table.
3.6 | Meta-analysis of sensitivity and 
specificity
Only 10 of the 30 included studies provided true positives, 
false positives, true negatives, and false negatives for the 
algorithms being tested (91 algorithms, Appendix S9A), al-
lowing limited opportunity for comprehensive meta-analysis. 
The bivariate diagnostic random-effects meta-analysis re-
vealed an overall sensitivity estimate of 88.6% (CI 85.7%–
91.0%), with an overall specificity estimate of 97.9% (CI 
98.5%–96.9%) false positive rate 0.021 (CI 0.015–0.031, 
Appendix S9B). This matches closely with our narrative as-
sessment that in general, sensitivity, and specificity estimates 
were high across studies. We were unable to proceed to a 
F I G U R E  6  Negative predictive value (NPV, %) and specificity (%) dot plots: Dots represent the NPV or specificity for each algorithm 
provided by studies, organized by country (6A = NPV, 6B = specificity), and by Quality Assessment of Diagnostic Accuracy Studies 2 
(QUADAS-2)19 score for overall risk of study bias or applicability concern (6C = NPV, 6D = specificity)
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valid bivariate meta-regression using study characteristics as 
covariates because the full spectrum of available study char-
acteristics from the 30 included studies were not represented 
in a small sample of only 10 studies. Furthermore, such a 
meta-regression would assume each of the within-study al-
gorithms providing estimates were independent, but they are 
not.
4 |  DISCUSSION
4.1 | Summary of findings
Overall, this systematic review illustrates that it is reasonable 
to use administrative healthcare data to identify people with 
epilepsy in epidemiological research, with studies tending to 
achieve high estimates (>80%) of PPV, sensitivity, NPV, and 
specificity. Because the large majority of validation studies 
in epilepsy have used hand-searched medical records as the 
diagnostic gold standard, limiting analysis to only such stud-
ies makes little difference to the overall results. Little dif-
ference is also seen in optimal epilepsy case-identification 
accuracy between the different ICD coding versions and be-
tween the ICD system and others. However, for a particular 
disease-coding system to perform well in and of itself, the 
most important elements seem to be algorithm structure and 
composition. There is a known trade-off relationship between 
PPV and sensitivity.56 In situations where researchers wish to 
prioritize achieving a high PPV, our findings suggest that the 
algorithm should consist of disease codes (ICD-10 G40-41, 
ICD-9 345) without symptom codes (ICD-10 R56, ICD-9 
780.3, 780.39), and one or more AEDs should be included. 
Most optimal case-identification algorithms capturing PPVs 
>80% (and even above 90%) used this basic arrangement, 
with or without the need to have the disease code registered 
more than once (Figure 4A). Where a balance needs to be 
struck between PPV and sensitivity, researchers may wish to 
choose disease codes alone (ie, without AEDs). This managed 
F I G U R E  7  Gold standard method 
dot plots: Dots represent the NPV (7A, %) 
or specificity (7B, %) for each algorithm, 
grouped by whether the reference standard 
used was exclusively medical records or 
other methods
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to retain both PPV and sensitivity >80% in several studies 
(Figure 4A,B). When sensitivity is the priority, our findings 
suggest that the algorithm should consist of symptom codes 
with one or more AEDs. We consistently show that an al-
gorithm consisting of one or more AEDs alone, while often 
able to provide a high sensitivity, is associated with very poor 
PPVs and should, therefore, not be used. High PPV may be 
preserved when one or more AEDs alone are used to try and 
identify children,14 although this was reported in one study 
and requires confirmation. For both PPV and sensitivity, 
there seems to be no added value in adding peripheral epi-
lepsy codes including: ICD-9 333.2 (myoclonus), 779 (con-
vulsions in new-borns), 780 (alteration of consciousness) 
except 780.3 or 0.39, or ICD-10 F80.3 (acquired aphasia 
with epilepsy). The algorithms consisting of long combina-
tions of core and peripheral epilepsy codes were no more 
likely to achieve a higher PPV or sensitivity for epilepsy than 
those using just core epilepsy disease codes (ICD-10 G40-41, 
ICD-9 345, Figures 4 and 5, Appendix S7). Although adding 
in a procedure code (such as EEG) to core epilepsy disease 
codes optimized sensitivity, it was associated with an unnec-
essary drop in PPV, and therefore it is unlikely to be help-
ful. The ICD system is largely used in administrative hospital 
settings worldwide, and one of its main purposes is to help 
summarize the incidence and prevalence of diseases on a na-
tional or worldwide basis.57 On the other hand, Read Codes 
are used primarily to create electronic patient records in the 
UK primary care system (although they can also be used to 
summarize disease incidence and prevalence).57 Taking these 
differences in function into account, our finding that there 
was little difference in the diagnostic accuracy of ICD codes 
and Read Codes for identification of epilepsy cases in ad-
ministrative healthcare records should be interpreted with 
caution, particularly as only three studies used Read Codes. 
Overall, epilepsy coding was particularly good at correctly 
identifying those without the disease, with estimates of NPV 
and specificity mostly remaining >90%, despite varying 
study characteristics.
Our other findings are that no countries appeared to out-
perform others in terms of overall case-identification accu-
racy using administrative data. Second, the factors seeming 
to be most consistently associated with lower optimal PPV or 
sensitivity estimates globally were modifiable, namely, study 
design elements that bring about high risk of bias or applica-
bility concern. To lower these risks, future validation studies 
should aim to clarify/adequately blind the reference standard 
F I G U R E  8  Forest plot showing the optimal diagnostic algorithms (8A = highest negative predictive value [NPV, %], 8B = highest 
specificity [%]) in each included study that estimated NPV or specificity, alongside various study characteristics. * = Studies that provided 
one NPV or specificity algorithm only. Bias = Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2)19 score for overall risk of 
study bias or applicability concern for that study. A and E: Accident and emergency; AED: Antiepileptic drug; CI: Confidence interval (%); 
EEG: Electroencephalography; EXE: Exception code; F25, 1O30, 667B., SC200: Epilepsy Read Codes; H: Hospitalization; ICD: International 
Classification of Diseases; ICD10 F80.3: Acquired aphasia with epilepsy; ICD10 G40: Epilepsy; ICD10 G41; Status epilepticus; ICD8 345: 
Epilepsy; ICD9 311, 300.4, 300, 300.02: Anxiety and depression codes; ICD9 333.2: Myoclonus; ICD9 345: Epilepsy; ICD9 779: Perinatal illness; 
ICD9 780.2: Syncope and collapse; ICD9 780.3: Convulsions; ICD9 780.31: Febrile convulsions; ICD9 780.39: Convulsions; P: Physician claim; 
RAI: Resident Assessment Instrument; VNS: Vagus nerve stimulation; Yr: year
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reader, avoid using unvalidated administrative data sets or 
AEDs as reference standards, administer the same reference 
standard to all participants, and account for any missing data 
by performing best- and worst-case sensitivity analyses. A 
third observation is that administrative settings that special-
ize in non-neurology and non-general medicine or accident 
and emergency patients appeared to perform worst in terms 
of epilepsy PPVs and sensitivities. These were psychiatric in-
patients, maternal disease registries, and long-term and com-
plex continuing care facilities. Optimal PPVs were no more 
than 37% in these settings, and sensitivities were no more 
than 74% (Figure 4A,B). However, as these studies were also 
part of the small handful of studies to not use medical records 
as the diagnostic gold standard (instead using AEDs or other 
administrative data sets as gold standard), the predominant 
cause of the lower accuracy estimates becomes less clear 
and will require further investigation in future studies using 
gold standard medical records. Finally, the data indicate that 
administrative setting and age of participants appeared to 
play little influence on optimal epilepsy case-identification 
accuracy.
Placing our results in context, the accuracy of adminis-
trative healthcare data in identifying epilepsy appears to be 
similar to that of other neurological diseases with rapidly 
progressive physical symptoms, such as multiple sclerosis 
(PPV 86%, sensitivity 84%, NPV 99%, specificity 100%)58 or 
motor neuron disease (PPV 55%–92%, sensitivity 75%–93%, 
NPV/specificity not reported).10
4.2 | Strengths and limitations
This review expands on findings of the 2012 US/Canada 
systematic review of this topic12 by now taking advantage 
of algorithms tested after that review within the United 
States or Canada (10 studies),32,34,40,42,44,45,47,48,52,54 and al-
gorithms tested outside of the United States and Canada (15 
studies).14,27-31,33,35,39,41,49-51,53,55 We also capture 10 more 
than the single study validating ICD-10,27,30,33,34,39,40,48,50-52 
and we review other non-ICD coding systems for the first 
time.14,31,41,49,55 It was concluded previously that a corrective 
factor would be necessary when relying on ICD-9 to iden-
tify epilepsy because the US Parko 200943 study had shown 
a PPV of 90% for a diagnosis of epilepsy or seizures and yet 
only a PPV of 62% for a diagnosis of epilepsy. However, we 
now demonstrate several other studies relying on ICD-9 in 
which no corrective factor was necessary to accurately iden-
tify epilepsy (see in Figure 4A, for example, the US study 
of De Jesus-Alvelo 2013).32 We also demonstrate this for 
ICD-10 (eg, Tan 201551 in Australia). It was also concluded 
F I G U R E  9  Forest plot showing the worst-performing diagnostic algorithms (9A = lowest negative predictive value [NPV, %], 9B = lowest 
specificity [%]) in each included study that estimated NPV or specificity, alongside various study characteristics. Bias = Quality Assessment of 
Diagnostic Accuracy Studies 2 (QUADAS-2)19 score for overall risk of study bias or applicability concern for that study. A and E: Accident and 
emergency; AED: Antiepileptic drug; CI: Confidence interval (%); EEG: Electroencephalography; EXE: Exception code; F25, 1O30, 667B., 
SC200: Epilepsy Read Codes; H: Hospitalization; ICD: International Classification of Diseases; ICD10 F80.3: Acquired aphasia with epilepsy; 
ICD10 G40: Epilepsy; ICD10 G41; Status epilepticus; ICD8 345: Epilepsy; ICD9 311, 300.4, 300, 300.02: Anxiety and depression codes; ICD9 
333.2: Myoclonus; ICD9 345: Epilepsy; ICD9 779: Perinatal illness; ICD9 780.2: Syncope and collapse; ICD9 780.3: Convulsions; ICD9 780.31: 
Febrile convulsions; ICD9 780.39: Convulsions; P: Physician claim; RAI: Resident Assessment Instrument; VNS: Vagus nerve stimulation; Yr: 
year
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previously that multiple epilepsy diagnoses over time are 
required to identify epilepsy using PPV. Although this is 
intuitive and was a condition for many of the optimal algo-
rithms with PPVs >80%, our much larger sample of studies 
demonstrates that it was not a requirement for all (Figure 4A, 
Appendix S7). This is the first systematic review of epilepsy 
validation studies to assess included studies for bias and ap-
plicability concern. We have been able to demonstrate that 
studies with a high risk of bias or applicability concern have a 
tendency toward lower PPV estimates, and we make recom-
mendations on how to reduce these risks. This is also the first 
systematic review of epilepsy validation studies to incorpo-
rate NPV and specificity estimates, demonstrating that these 
estimates are generally favorable for this condition. Our al-
gorithm look-up table (Appendix S7) is a novel resource that 
should help future researchers screen epilepsy patients for in-
clusion into studies recruiting from administrative data sets.
This review demonstrates that there is currently limited 
scope for detailed meta-analysis of epilepsy validation data, 
indicating that this an area that will require more investiga-
tion in the future as more data become available. The forest 
plots (Figures 4, 5, 8, 9, Appendix S9) suggest that hetero-
geneity is low, but this would benefit from further investi-
gation in a meta-regression, which was not possible in the 
current review because of limitations in the available data. 
Furthermore, we were unable to assess for publication bias 
due to the absence of a well-established technique to do so in 
validation reviews.10,11
5 |  CONCLUSIONS
This review helps researchers in deciding on optimal case-
identification methods when using administrative health-
care data to capture persons with epilepsy. It also improves 
our understanding of the likely accuracy of global esti-
mates for the incidence and prevalence of epilepsy, which 
have largely been made using administrative data. Our 
findings are consistent with the hypothesis that administra-
tive epilepsy data accurately identify epilepsy cases, with 
optimal estimates of PPV, sensitivity, NPV, and specific-
ity >80% in the majority of studies. This is likely to be 
sufficient for most epidemiological studies, although we 
show that careful consideration is needed when choosing 
algorithm structure and code composition for PPV and 
sensitivity. Although the published algorithms are a use-
ful approximation for accuracy and there are several epi-
lepsy validation studies available around the world, future 
investigators should still aim to validate putatively selected 
algorithms within their own data sets first in order to help 
maintain transparency in the likely accuracy of subsequent 
study findings.
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